糖皮质激素受体引起去势抵抗性前列腺癌耐药的机理及治疗
Mechanism and Treatment of Drug Resistance in Castration-Resistant Prostate Cancer Caused by Glucocorticoid Receptors
摘要: 前列腺癌是威胁男性健康的重要疾病。但在临床上，不同的治疗手段在后期都会引起不同程度的耐药，其中糖皮质激素的过度表达是引起耐药的重要形式。因此，针对雄激素受体和糖皮质激素受体的联合治疗，逐渐成为了治疗前列腺癌的重要方式。本文总结了糖皮质激素受体引起去势抵抗性前列腺癌耐药的机理，以及用于治疗的双靶点化合物。
Abstract: Prostate cancer is an important disease that threatens men’s health. However, clinically, different treatment methods will cause different degrees of drug resistance in the later stage, among which the overexpression of glucocorticoids is an important form of drug resistance. Therefore, combination therapy for androgen receptors and glucocorticoid receptors has gradually become an important way to treat prostate cancer. This paper summarises the mechanisms by which glucocorticoid receptors cause drug resistance in depot-resistant prostate cancer and the dual-target compounds used for treatment.
文章引用：李晨帆, 康晋伟. 糖皮质激素受体引起去势抵抗性前列腺癌耐药的机理及治疗[J]. 药物化学, 2023, 11(1): 18-23. https://doi.org/10.12677/HJMCe.2023.111004

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Crona, D.J., and Whang, Y.E. (2017) Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. Cancers (Basel), 9, Article 67. [Google Scholar] [CrossRef] [PubMed]
[3] Korpal, M., Korn, J.M., Gao, X., et al. (2013) An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). Cancer Discovery, 3, 1030-1043. [Google Scholar] [CrossRef] 
[4] Branch, J.R., Bush, T.L., Pande, V., et al. (2021) Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 20, 763-774. [Google Scholar] [CrossRef] 
[5] Takeda, D.Y., Spisak, S., Seo, J.H., et al. (2018) A Somat-ically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell, 174, 422-432e13. [Google Scholar] [CrossRef] [PubMed]
[6] Bohl, C.E., Gao, W., Miller, D.D., et al. (2005) Struc-tural Basis for Antagonism and Resistance of Bicalutamide in Prostate Cancer. Proceedings of the National Academy of Sciences of the United States of America, 102, 6201-6206. [Google Scholar] [CrossRef] [PubMed]
[7] Bubley, G.J., and Balk, S.P. (2017) Association between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 2103-2105. [Google Scholar] [CrossRef] 
[8] Kocak, A., and Yildiz, M. (2022) Molecular Dynamics Simulations Reveal the Plausible Agonism/Antagonism Mechanism by Steroids on Androgen Receptor Mutations. Journal of Molec-ular Graphics and Modelling, 111, Article ID: 108081. [Google Scholar] [CrossRef] [PubMed]
[9] Balbas, M.D., Evans, M.J., Hosfield, D.J., et al. (2013) Overcoming Mutation-Based Resistance to Antiandrogens with Rational Drug Design. eLife, 2, e00499. [Google Scholar] [CrossRef] 
[10] Arora, V.K., Schenkein, E., Murali, R., et al. (2013) Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell, 155, 1309-1322. [Google Scholar] [CrossRef] [PubMed]
[11] Farrow, J.M., Yang, J.C. and Evans, C.P. (2014) Autophagy as a Modulator and Target in Prostate Cancer. Nature Reviews Urology, 11, 508-516. [Google Scholar] [CrossRef] [PubMed]
[12] Hoshi, S., Meguro, S., Imai, H., et al. (2021) Upregulation of Gluco-corticoid Receptor-Mediated Glucose Transporter 4 in Enzalutamide-Resistant Prostate Cancer. Cancer Science, 112, 1899-1910. [Google Scholar] [CrossRef] [PubMed]
[13] Serritella, A.V., Shevrin, D., Heath, E.I., et al. (2022) Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Pros-tate Cancer. Clinical Cancer Research, 28, 1549-1559. [Google Scholar] [CrossRef] 
[14] Adelaiye-Ogala, R., Gryder, B.E., Nguyen, Y.T.M., et al. (2020) Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocor-ticoid Receptor. Molecular Cancer Therapeutics, 19, 1436-1447. [Google Scholar] [CrossRef] 
[15] Kurmis, A.A., Yang, F., Welch, T.R., et al. (2017) A Pyr-role-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer. Cancer Research, 77, 2207-2212. [Google Scholar] [CrossRef] 
[16] Cheng, K., Liu, X., Chen, L., et al. (2018) Alpha-Viniferin Activates Autophagic Apoptosis and Cell Death by Reducing Glucocorticoid Receptor Expression in Castration-Resistant Prostate Cancer Cells. Medical Oncology, 35, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[17] Rosette, C., Agan, F.J., Rosette, N., et al. (2020) The Dual An-drogen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors That Have Ac-quired GR-Mediated Resistance to AR Blockade. Molecular Cancer Therapeutics, 19, 2256-2266. [Google Scholar] [CrossRef] 
[18] Ide, H., Inoue, S., Mizushima, T., et al. (2020) Compound A Inhibits Urothelial Tumorigenesis via both the Androgen Receptor and Glucocorticoid Receptor Signaling Pathways. American Journal of Translational Research, 12, 1779-1788.